57. Vandy FC, Stabler C, Eliassen AM, et al. Soluble P-selectin for the diagnosis of lower extremity

deep venous thrombosis. J Vasc Surg Venous Lymphat Disord 2013;1:117–125.

58. Chauhan AK, Kisucka J, Lamb CB, et al. von Willebrand factor and factor VIII are independently

required to form stable occlusive thrombi in injured veins. Blood 2007;109:2424–2429.

59. Day SM, Reeve JL, Pedersen B, et al. Macrovascular thrombosis is driven by tissue factor derived

primarily from the blood vessel wall. Blood 2005;105:192–198.

60. Swystun LL, Shin LY, Beaudin S, et al. Chemotherapeutic agents doxorubicin and epirubicin induce

a procoagulant phenotype on endothelial cells and blood monocytes. J Thromb Haemost 2009;7:619–

626.

61. Tesselaar ME, Romijn FP, van der Linden IK, et al. Microparticle-associated tissue factor activity in

cancer patients with and without thrombosis. J Thromb Haemost 2009;7:1421–1423.

62. Manly DA, Wang J, Glover SL, et al. Increased microparticle tissue factor activity in cancer patients

with venous thromboembolism. Thromb Res 2010;125:511–512.

63. Ripplinger CM, Kessinger CW, Li C, et al. Inflammation modulates murine venous thrombosis

resolution in vivo: assessment by multimodal fluorescence molecular imaging. Arterioscler Thromb

Vasc Biol 2012;32:2616–2624.

64. Deatrick KB, Luke CE, Elfline MA, et al. The effect of matrix metalloproteinase 2 and matrix

metalloproteinase 2/9 deletion in experimental post-thrombotic vein wall remodeling. J Vasc Surg

2013;58:1375–1384.e2.

65. Deatrick KB, Obi A, Luke CE, et al. Matrix metalloproteinase-9 deletion is associated with

decreased mid-term vein wall fibrosis in experimental stasis DVT. Thromb Res 2013;132:360–366.

66. Wakefield TW, Strieter RM, Wilke CA, et al. Venous thrombosis-associated inflammation and

attenuation with neutralizing antibodies to cytokines and adhesion molecules. Arterioscler Thromb

Vasc Biol 1995;15:258–268.

67. Varma MR, Varga AJ, Knipp BS, et al. Neutropenia impairs venous thrombosis resolution in the rat.

J Vasc Surg 2003;38:1090–1098.

161

http://surgerybook.net/

68. Stewart GJ. Neutrophils and deep venous thrombosis. Haemostasis 1993; 23(suppl 1):127–140.

69. Varma MR, Moaveni DM, Dewyer NA, et al. Deep vein thrombosis resolution is not accelerated

with increased neovascularization. J Vasc Surg 2004;40:536–542.

70. Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl

Acad Sci 2010;107:15880–15885.

71. Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity

via neutrophil serine proteases. Nat Med 2010;16:887–896.

72. Diaz JA, Fuchs TA, Jackson TO, et al.; for the Michigan Research Venous Group. Plasma DNA is

elevated in patients with deep vein thrombosis. Journal of vascular surgery. J Vasc Surg Venous

Lymphat Disord 2013;1(4). doi: 10.1016/j.jvsv.2012.12.002.

73. Saha P, Humphries J, Modarai B, et al. Leukocytes and the natural history of deep vein thrombosis:

current concepts and future directions. Arterioscler Thromb Vasc Biol 2011;31:506–512.

74. Humphries J, McGuinness CL, Smith A, et al. Monocyte chemotactic protein-1 (MCP-1) accelerates

the organization and resolution of venous thrombi. J Vasc Surg 1999;30:894–899.

75. Henke PK, Pearce CG, Moaveni DM, et al. Targeted deletion of CCR2 impairs deep vein thrombosis

resolution in a mouse model. J Immunol 2006;177:3388–3397.

76. Deatrick KB, Wakefield TW, Henke PK. Chronic venous insufficiency: current management of

varicose vein disease. Am Surg 2010;76:125–132.

77. Northeast AD, Soo KS, Bobrow LG, et al. The tissue plasminogen activator and urokinase response

in vivo during natural resolution of venous thrombus. J Vasc Surg 1995;22:573–579.

78. Soo KS, Northeast AD, Happerfield LC, et al. Tissue plasminogen activator production by monocytes

in venous thrombolysis. J Pathol 1996;178:190–194.

79. Singh I, Burnand KG, Collins M, et al. Failure of thrombus to resolve in urokinase-type plasminogen

activator gene-knockout mice: rescue by normal bone marrow-derived cells. Circulation

2003;107:869–875.

80. Evans CE, Humphries J, Waltham M, et al. Upregulation of hypoxia-inducible factor 1 alpha in local

vein wall is associated with enhanced venous thrombus resolution. Thromb Res 2011;128:346–351.

81. Lim CS, Qiao X, Reslan OM, et al. Prolonged mechanical stretch is associated with upregulation of

hypoxia-inducible factors and reduced contraction in rat inferior vena cava. J Vasc Surg

2011;53:764–773.

82. Myers DD Jr, Henke PK, Bedard PW, et al. Treatment with an oral small molecule inhibitor of P

selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosis. J Vasc

Surg 2006;44:625–632.

83. Moaveni DK, Lynch EM, Luke C, et al. Vein wall re-endothelialization after deep vein thrombosis is

improved with low-molecular-weight heparin. J Vasc Surg 2008;47:616–624.

84. Stenberg B, Bylock A, Risberg B. Effect of venous stasis on vessel wall fibrinolysis. Thromb Haemost

1984;51:240–242.

85. Henke PK, Varma MR, Moaveni DK, et al. Fibrotic injury after experimental deep vein thrombosis

is determined by the mechanism of thrombogenesis. Thromb Haemost 2007;98:1045–1055.

86. Wojcik BM, Wrobleski SK, Hawley AE, et al. Interleukin-6: a potential target for post-thrombotic

syndrome. Ann Vasc Surg 2011;25:229–239.

87. Grainger DJ, Wakefield L, Bethell HW, et al. Release and activation of platelet latent TGF-beta in

blood clots during dissolution with plasmin. Nat Med 1995;1:932–937.

88. Diaz JA, Ballard-Lipka NE, Farris DM, et al. Impaired fibrinolytic system in ApoE gene-deleted mice

with hyperlipidemia augments deep vein thrombosis. J Vasc Surg 2012;55(3):815–822.

89. Deatrick KB, Eliason JL, Lynch EM, et al. Vein wall remodeling after deep vein thrombosis involves

matrix metalloproteinases and late fibrosis in a mouse model. J Vasc Surg 2005;42:140–148.

90. Obi AT, Diaz JA, Ballard-Lipka NL, et al. Plasminogen activator-1 overexpression decreases

experimental postthrombotic vein wall fibrosis by a non-vitronectin-dependent mechanism. J

Thromb Haemost 2014;12:1353–1363.

91. Myers DD Jr, Henke PK, Bedard PW, et al. Treatment with an oral small molecule inhibitor of P

selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosis. J Vasc

Surg 2006;44:625–632.

162

http://surgerybook.net/

92. Wojcik BM, Wrobleski SK, Hawley AE, et al. Interleukin-6: a potential target for post-thrombotic

syndrome. Ann Vasc Surg 2011;25:229–239.

93. Baldwin JF, Sood V, Elfline MA, et al. The role of urokinase plasminogen activator and plasmin

activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis. J Vasc Surg

2012;56:1089–1097.

94. Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008;451:914–918.

95. Ross R. Atherosclerosis–an inflammatory disease. N Eng J Med 1999;340:115–126.

96. Hathcock JJ. Flow effects on coagulation and thrombosis. Arterioscler Thromb Vasc Biol

2006;26:1729–1737.

97. Dentali F, Squizzato A, Ageno W. The metabolic syndrome as a risk factor for venous and arterial

thrombosis. Semin Thromb Hemost 2009;35:451–457.

98. Chan MY, Andreotti F, Becker RC. Hypercoagulable states in cardiovascular disease. Circulation

2008;118:2286–2297.

99. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of

venous thromboembolism. N Eng J Med 2009;360(18):1851–1861.

100. Gangireddy C, Rectenwald JR, Upchurch GR, et al. Risk factors and clinical impact of postoperative

symptomatic venous thromboembolism. J Vasc Surg 2007;45:335–341; discussion 341–332.

101. Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc

Biol 2008;28:370–372.

102. Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the

community. Thromb Haemost 2001;86:452–463.

103. Caprini JA, Arcelus JI, Reyna JJ. Effective risk stratification of surgical and nonsurgical patients for

venous thromboembolic disease. Semin Hematol 2001;38:12–19.

104. Pannucci CJ, Laird S, Dimick JB, et al. A validated risk model to predict 90-day VTE events in postsurgical patients. Chest 2013;145(3):567–573.

105. Gould MK, Garcia DA, Wren SM, et al.; American College of Chest Physicians. Prevention of VTE in

nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed:

American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest

2012;141:e227S–e277S.

106. van den Berg YW, Osanto S, Reitsma PH, et al. The relationship between tissue factor and cancer

progression: insights from bench and bedside. Blood 2012;119:924–932.

107. Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol. 2009;27:4834–

4838.

108. Khorana AA. The NCCN clinical practice guidelines on venous thromboembolic disease: strategies

for improving VTE prophylaxis in hospitalized cancer patients. Oncologist 2007;12:1361–1370.

109. Twig G, Zandman-Goddard G, Szyper-Kravitz M, et al. Systemic thromboembolism in inflammatory

bowel disease: mechanisms and clinical applications. Ann N Y Acad Sci 2005;1051:166–173.

110. Merrill A, Millham F. Increased risk of postoperative deep vein thrombosis and pulmonary

embolism in patients with inflammatory bowel disease: a study of national surgical quality

improvement program patients. Arch Surg 2012;147:120–124.

111. Selby R, Geerts W, Ofosu FA, et al. Hypercoagulability after trauma: hemostatic changes and

relationship to venous thromboembolism. Thromb Res 2009;124:281–287.

112. Shackford SR, Davis JW, Hollingsworth-Fridlund P, et al. Venous thromboembolism in patients

with major trauma. Am J Surg 1990;159:365–369.

113. Paffrath T, Wafaisade A, Lefering R, et al.; Trauma Registry of DGU. Venous thromboembolism

after severe trauma: incidence, risk factors and outcome. Injury 2010;41:97–101.

114. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the

antiphospholipid-antibody syndrome. N Eng J Med 1995;332:993–997.

115. Carreras LO, Defreyn G, Machin SJ, et al. Arterial thrombosis, intrauterine death and “lupus”

antiocoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet

1981;1:244–246.

116. Comp PC, DeBault LE, Esmon NL, et al. Human thrombomodulin is inhibited by IgG from two

patients with non-specific anticoagulants (abstract). Blood 1983;62:244–246.

163